What matters in preeclampsia are the associated adverse outcomes: The view from Canada

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 2, 2008, Pages 110-115

  Von Dadelszen, Peter ^a,b,c   Magee, Laura ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; HEPARIN;

ADVERSE OUTCOME; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CANADA; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG TREATMENT FAILURE; HIGH RISK POPULATION; HUMAN; INFANT MORTALITY; INTRAUTERINE GROWTH RETARDATION; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; MATERNAL MORTALITY; PHENOTYPE; PLACENTA; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMALL FOR DATE INFANT;

CANADA; FEMALE; HUMANS; HYPERTENSION; PHENOTYPE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; RISK FACTORS;

EID: 41849105794     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282f733a2     Document Type: Review

References (20)

1. Liu S, Heaman M, Sauve R, et al. An analysis of antenatal hospitalization in Canada, 1991-2003. Matern Child Health J 2007; 11:181-187. This paper presents national level data from a uniformly public maternity system about the indications for and temporal trends in antenatal hospitalization over a 12-year period.
2. Magee LA, Helewa M, Rey E, et al. Diagnosis, evaluation and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can (in press).
3. Knight M. Eclampsia in the United Kingdom 2005. BJOG 2007; 114:1072-1078. This paper updates the previous BEST study of Douglas and Redman, and provides data to support the utility of magnesium sulphate prophylaxis, and highlights the increasing occurrence of eclampsia in women with occult preeclampsia (in that they did not first present with proteinuric gestational hypertension).
4. Magee LA, von Dadelszen P, Chan S, et al. The Control of Hypertension In Pregnancy Study pilot trial. BJOG 2007; 114:770e13-770e20. This paper presents data from the CHIPS Pilot Trial. The CHIPS Pilot determined that the proposed interventions for the CHIPS Trial result in differential blood pressure control and that less tight control of maternal hypertension in nonproteinuric hypertension (preexisting and gestational) may be associated with improved perinatal outcomes.
5. Menzies J, Magee LA, MacNab YC, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy 2007; 26:447-462.
6. Jenkins LD, Powers RW, Adotey M, et al. Maternal leptin concentrations are similar in African Americans and Caucasians in normal pregnancy, preeclampsia and small-for-gestational-age infants. Hypertens Pregnancy 2007; 26:101-109. This paper is important in that it examines the changes in lipid metabolism that are specific to preeclampsia and not shared with normotensive IUGR.
7. Smith GC, Crossley JA, Aitken DA, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007; 109:1316-1324. Using a nested case-control design from a maternal serum screen biobank, rather than a preeclampsia-related cohort, this paper raises questions about the relationship between angiogenic factors and the risk of preeclampsia, as well as the other placental complications of pregnancy.
8. Toal M, Chan C, Fallah S, et al. Usefulness of a placental profile in high-risk pregnancies. Am J Obstet Gynecol 2007; 196:363-367. This paper adds to the increasing evidence to support risk stratification through maternal serum and ultrasound markers of placental development.
9. Whittle W, Chaddha V, Wyatt P, et al. Ultrasound detection of placental insufficiency in women with 'unexplained' abnormal maternal serum screening results. Clin Genet 2006; 69:97-104. This paper adds to the increasing evidence to support risk stratification through maternal serum and ultrasound markers of placental development.
10. Rodger MA, Paidas M. Do thrombophilias cause placenta-mediated pregnancy complications? Semin Thromb Hemost 2007; 33:597-603. This review usefully submits the relationship between both inherited and acquired thrombophilias with adverse pregnancy outcomes, including preeclampsia, to Sir Bradford Hill's criteria. By most criteria, the requirements for a causal relationship are not met.
11. Newhouse SM, Davidge ST, Winkler-Lowen B, et al. In vitro differentiation of villous trophoblasts from pregnancies complicated by intrauterine growth restriction with and without preeclampsia. Placenta 2007; 28:999-1003.
12. Chen XK, Wen SW, Smith G, et al. Pregnancy-induced hypertension and infant mortality: Roles of birthweight centiles and gestational age. BJOG 2007; 114:24-31. Using a large US administrative dataset, this study has provided further support for the conjecture that aspects of the maternal syndrome of preeclampsia may afford perinatal protection.
13. Poston L, Briley AL, Seed PT, et al. Vitamin Cand vitamin E in pregnant women at risk for preeclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006; 367:1145-1154. This international RCT failed to find any benefit from the use of combined vitamins C and E in the prevention of preeclampsia in either low or high risk populations. Furthermore, the use of these vitamins may confer additional perinatal risks. Further data from a halted Canadian-based international RCT and the ongoing UC NICHD RCT are awaited.
14. Rumbold AR, Crowther CA, Haslam RR, et al. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 2006; 354:1796-1806. This international RCT failed to find any benefit from the use of combined vitamins C and E in the prevention of preeclampsia in either low or high risk populations. Furthermore, the use of these vitamins may confer additional perinatal risks. Further data from a halted Canadian-based international RCT and the ongoing UC NICHD RCT are awaited.
15. Menzies J, Magee LA, Li J, et al. Instituting surveillance guidelines and adverse outcomes in preeclampsia. Obstet Gynecol 2007; 110:121-127. Using a standardised guideline for the initial inpatient assessment and ongoing surveillance of women admitted to a tertiary perinatal unit withy preeclampsia was associated with a large and significant fall in adverse maternal outcomes.
16. Newstead J, von Dadelszen P, Magee LA. Preeclampsia and future cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5:283-294.
17. Magee LA, von Dadelszen P. Preeclampsia and increased cardiovascular risk. BMJ 2007; 335:945-946.
18. Girouard J, Giguere Y, Moutquin JM, Forest JC. Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. Hypertension 2007; 49:1056-1062.
19. Macdonald SE, Walker M, Ramshaw H, et al. Hypertensive disorders of pregnancy and long-term risk of hypertension: what do Ontario prenatal care providers know, and what do they communicate? J Obstet Gynaecol Can 2007; 29:705-710. This paper emphasizes the knowledge gap that exists between the data relating preeclampsia with lifelong cardiovascular risk and what clinicians are informing each other and their patients.
20. Abenhaim HA, Kinch RA, Morin L, et al. Effect of prepregnancy body mass index categories on obstetrical and neonatal outcomes. Arch Gynecol Obstet 2007; 275:39-43.